New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility,further examination by the investigator is necessary. Inclusion Criteria:

• Hospitalized/chronic care pediatric patients (birth through 17 years)

• Known infections due to vancomycin-resistant enterococcus species, including diagnosisof hospital-acquired pneumonia, complicated skin and skin structure infections,catheter-related bacteremia, bacteremia of unidentified source, and other infections

• Requires a minimum of 3 days of IV medication

• Patients with mixed infections due to VRE & gram negative bacteria are allowed toenroll in the study. For most of the infections, 2 or more of additional symptoms arerequired.

Exclusion Criteria:

• Potentially effective concomitant antibiotic

• A high surgical cure rate

• Medical conditions which would preclude clinical evaluation or require treatment oflonger duration than 28 days

• 24 hours of antibiotic treatment within 48 hours of study entry (unless pre-approved)

• Having an infected device that could not be removed